Tamoxifen-induced adduct formation and cell stress in human endometrial glands

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 200-207

  Andersson, Helén ^a   Helmestam, Malin ^b   Zebrowska, Anna ^a   Olovsson, Matts ^b   Brittebo, Eva ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CHAPERONE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GLUCOSE REGULATING PROTEIN 78; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REGULATOR PROTEIN; SULFOTRANSFERASE; SULFOTRANSFERASE 2A1; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; CELL STRESS; CONTROLLED STUDY; DNA ADDUCT; DRUG ACTIVATION; DRUG CYTOTOXICITY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOPLASMIC RETICULUM STRESS; EPITHELIUM CELL; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROLIFERATIVE PHASE; PROTEIN EXPRESSION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CASPASE 3; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ENDOMETRIUM; EPITHELIUM; FEMALE; FOLLICULAR PHASE; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HUMANS; LUTEAL PHASE; NF-KAPPA B; OXIDOREDUCTASES, N-DEMETHYLATING; STRESS, PHYSIOLOGICAL; STROMAL CELLS; SULFOTRANSFERASES; TAMOXIFEN;

EID: 73149095813     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029488     Document Type: Article

References (40)

1. Annas A and Brittebo EB (1998) Localization of cytochrome P4501A1 and covalent binding of a mutagenic heterocyclic amine in blood vessel endothelia of rodents. Toxicology 129:145-156.
2. Beland FA, Churchwell MI, Hewer A, Phillips DH, da Costa GG, and Marques MM (2004) Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling. Biochem Biophys Res Commun 320:297-302.
3. Brittebo EB and Brandt I (1997) Cell- and tissue-specific metabolic activation of chemicals as determined by autoradiography: in vitro-in vivo correlations. Toxicol In Vitro 11:417-421.
4. Bursch W, Karwan A, Mayer M, Dornetshuber J, Fröhwein U, Schulte-Hermann R, Fazi B, Di Sano F, Piredda L, Piacentini M, et al. (2008) Cell death and autophagy: cytokines, drugs, and nutritional factors. Toxicology 254:147-157.
5. Campbell S, Larsen J, Seif MW, Allen TD, Knox F, Jones CJ, and Aplin JD (2000) Mosaic characteristics of human endometrial epithelium in vitro: analysis of secretory markers and cell surface ultrastructure. Mol Hum Reprod 6:41-49.
6. Carmichael PL, Sardar S, Crooks N, Neven P, Van Hoof I, Ugwumadu A, Bourne T, Tomas E, Hellberg P, Hewer AJ, et al. (1999) Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20:339-342.
7. Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK, and Phillips DH (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479.
8. Cribb AE, Peyrou M, Muruganandan S, and Schneider L (2005) The endoplasmic reticulum in xenobiotic toxicity. Drug Metab Rev 37:405-442.
9. Dehal SS and Kupfer D (1996) Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res 56:1283-1290.
10. Dehal SS and Kupfer D (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 27:681-688.
11. Desta Z, Ward BA, Soukhova NV, and Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075.
12. Dunn BK and Ford LG (2001) From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J 7:144-157.
13. Ernst M, Schmid C, and Froesch ER (1989) Phenol red mimics biological actions of estradiol: enhancement of osteoblast proliferation in vitro and of type I collagen gene expression in bone and uterus of rats in vivo. J Steroid Biochem 33:907-914.
14. Franzén A and Brittebo EB (2005) Toxicant-induced ER-stress and caspase activation in the olfactory mucosa. Arch Toxicol 79:561-570.
15. Gielen SC, Kühne LC, Ewing PC, Blok LJ, and Burger CW (2005) Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer 12:1037-1049.
16. Granberg L, Ostergren A, Brandt I, and Brittebo EB (2003) CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells. Drug Metab Dispos 31:259-265.
17. Greaves P, Goonetilleke R, Nunn G, Topham J, and Orton T (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924.
18. Hachisuga T, Emoto M, Kawarabayashi T, Kamihara Y, and Nabeshima K (2009) Endometrial cytologic findings in tamoxifen-treated breast cancer patients. Acta Cytol 53:24-28.
19. Hemminki K, Rajaniemi H, Lindahl B, and Moberger B (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56:4374-4377.
20. Hukkanen J, Mäntylä M, Kangas L, Wirta P, Hakkola J, Paakki P, Evisalmi S, Pelkonen O, and Raunio H (1998) Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol Toxicol 82:93-97.
21. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39.
22. Johansson EB and Tjälve H (1978) The distribution of [14C]dimethylnitrosamine in mice. Autoradiographic studies in mice with inhibited and noninhibited dimethylnitrosamine metabolism and a comparison with the distribution of [14C]formaldehyde. Toxicol Appl Pharmacol 45:565-575.
23. Kim SY, Laxmi YR, Suzuki N, Ogura K, Watabe T, Duffel MW, and Shibutani S (2005a) Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers. Drug Metab Dispos 33:1673-1678.
24. Kim SY, Suzuki N, Laxmi YR, McGarrigle BP, Olson JR, Sharma M, Sharma M, and Shibutani S (2005b) Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen. Chem Res Toxicol 18:889-895.
25. Kim SY, Suzuki N, Laxmi YR, and Shibutani S (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 36:199-218.
26. Mourits MJ, Hollema H, De Vries EG, Ten Hoor KA, Willemse PH, and Van Der Zee AG (2002) Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol 33:341-346.
27. Notley LM, Crewe KH, Taylor PJ, Lennard MS, and Gillam EM (2005) Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives. Chem Res Toxicol 18:1611-1618.
28. Park BK, Pirmohamed M, and Kitteringham NR (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 68:385-424.
29. Phillips DH, Hewer A, Horton MN, Cole KJ, Carmichael PL, Davis W, and Osborne MR (1999) N-demethylation accompanies alpha-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis 20:2003-2009.
30. Phillips DH, Hewer A, Osborne MR, Cole KJ, Churchill C, and Arlt VM (2005) Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis 20:297-303.
31. Pole JC, Gold LI, Orton T, Huby R, and Carmichael PL (2005) Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen. Toxicology 206:91-109.
32. Ray S, Hou X, Zhou HE, Wang H, and Das SK (2006) Bip is a molecular link between the phase I and phase II estrogenic responses in uterus. Mol Endocrinol 20:1825-1837.
33. Rubin GL, Harrold AJ, Mills JA, Falany CN, and Coughtrie MW (1999) Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy. Mol Hum Reprod 5:995-1002.
34. Shang Y (2006) Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6:360-368.
35. Sharma M, Shubert DE, Sharma M, Lewis J, McGarrigle BP, Bofinger DP, and Olson JR (2003a) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact 146:237-249.
36. Sharma M, Shubert DE, Sharma M, Rodabaugh KJ, McGarrigle BP, Vezina CM, Bofinger DP, and Olson JR (2003b) Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. Biochem Biophys Res Commun 307:157-164.
37. Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP, and Pearl ML (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21:1461-1467.
38. Shibutani S, Shaw PM, Suzuki N, Dasaradhi L, Duffel MW, and Terashima I (1998) Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 19:2007-2011.
39. Singh MN, Stringfellow HF, Walsh MJ, Ashton KM, Paraskevaidis E, Abdo KR, Martin-Hirsch PL, Phillips DH, and Martin FL (2008) Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology 249:85-90.
40. Stackievicz R, Drucker L, Radnay J, Beyth Y, Yarkoni S, and Cohen I (2001) Tamoxifen modulates apoptotic pathways in primary endometrial cell cultures. Clin Cancer Res 7:415-420.